> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 10 Observations in Hospira FDA-483
- URL: https://www.fdaweb.com/10-observations-in-hospira-fda-483-3/
- Published: 2018-02-23T12:00:00.000Z
- Updated: 2026-09-14T23:25:10.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140829

FDA has released the FDA-483 issued following a 10/16-10/27/17 inspection at a Hospira sterile drug manufacturing facility in McPherson, KS. The 10 inspection [observations](https://www.fda.gov/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/UCM596899?ref=fdaweb.com) were: 

- failing to thoroughly review any unexplained discrepancy whether the batch has been already distributed;
- employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions;
- equipment used in the manufacture, processing, packing, or holding of drug products is not of appropriate design to facilitate operations for its intended use;
- reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration;
- cleaning products designed to prevent microbiological contamination of drug products purporting to be sterile are not followed;
- failing to submit a NDA-Field Alert Report within three working days of receipt of information concerning a failure of one or more distributed batches of a drug to meet the specifications established for it in the application;
- written records of investigations into the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up;
- procedures describing handling of written and oral complaints related to drug products are deficiently written;
- failing to record and/or justify deviations from written test procedures; and
- failing to store drug products under appropriate conditions of temperature so that their identity, strength, quality, and purity are not affected.